All Blogs
Sep 15, 2022
Aerin Medical’s RhinAer Stylus; CE Mark for Haemonetics’s VASCADE Vascular Closure Device; J&J Vision Launches ACUVUE OASYS MAX 1-Day; Olympus Launches VISERA ELITE III Surgical Visualization Platform; GlucoRx’s Non-Invasive Glucose Monitoring Platform; Medtronic-BioIntelliSense’s Partnership; Corindus’s CorPath GRX Neurovascular System Trial; GE & Lantheus [18F]flurpiridaz PET Radiotracer Trial; Pulmonx’s AeriSeal System Trial; AtriAN’s Second Study on Cardioneuroablation
Johnson & Johnson Vision Launches New Contact Lens Innovation ACUVUE® OASYS MAX 1-Day for Meeting the Needs of Digitally Intense Lifestyles On September 12, 2022, Johnson & Johnson Vision, a part of Johnson & Johnson and a global leader in the eyecare market, had announced the launch of its newest in...
Read More...
Sep 14, 2022
Navigating the Most Use Cases of Robotic Process Automation (RPA) in Healthcare
In today’s highly competitive and dynamic business environment, every organization works in the direction to improve its process quality, speed, and productivity. To handle these critical aspects and provide better results, we have several new technologies in the market that can address the underlying issue in the ...
Read More...
Sep 13, 2022
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...
Read More...
Sep 12, 2022
How Emerging Pipeline Therapies Will Unfold the Severe Asthma Treatment Market Dynamics?
Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...
Read More...
Sep 09, 2022
Treatment to Clinical Development – A Bumpy Journey for Pancreatic Cancer
Treatment for pancreatic cancer patients is challenging and not well defined, especially for patients with disease progression or adverse events seen after initial treatment. Studies suggest that, after diagnosis, about 22% of pancreatic cancer patients, regardless of their clinical stage of cancer, receive no trea...
Read More...
Sep 09, 2022
Alopecia Areata Treatment: Which Pipeline Therapy Will Steal the Spotlight?
Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options are available. The main goal of treatment is...
Read More...
Sep 08, 2022
eCential Robotics’s Surgical Robotic Platform for Spine Surgery; Baxter Gets 510(k) Clearance for Syringe Pump; Medical Microinstruments’s NanoWrist Instruments; Magnus’ SAINT Neuromodulation System; Henry Schein Acquires Midway Dental Supply
eCential Robotics Receives FDA Clearance for its Surgical Robotic Platform for Spine Surgery The FDA has approved a robotic spinal surgery platform designed to assist human surgeons by automating several steps of spinal procedures. The platform, developed by eCential Robotics, combines intraoperative 2D and 3D i...
Read More...
Sep 07, 2022
How Is Digital Therapeutics Reshaping the Future of Healthcare?
Over the past few years, there has been a massive advancement and adoption in the digital health segment. The segment is likely to exhibit growth and onward trend in the coming years as well, owing to the huge capital investment and positive approach by the healthcare authorities Similar, some key factors, such as ...
Read More...
Sep 06, 2022
AstraZeneca’s Imfinzi for Biliary Tract Cancer; FDA Clears Boehringer’s Spesolimab; Novo Nordisk to Acquire Forma Therapeutics; Sanofi’s Xenpozyme Approved for ASMD; Another FDA Approval to Azurity’s Konvomep; Amgen’s Lumakras Trial Results; FDA Grants Priority Review to Sanofi & Sobi’s efanesoctocog alfa; Neurocrine Bio to Takeover UK Biotech Diurnal
FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Read More...
Sep 05, 2022
Which Pipeline Therapy Will Change the WHIM Syndrome Treatment Market Scenario?
WHIM Syndrome possessing limited cures paves the way toward evolving demand for novel treatment therapies. Moreover, the increasing prevalence and R&D activities drive the WHIM syndrome treatment market forward. As per DelveInsight’s latest WHIM Syndrome epidemiology report, there were approximately 180 diag...
Read More...